NCT01504542View on ClinicalTrials.gov

Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Non-small Cell Lung Cancer
Interventions
BIOLOGICAL

HS110 vaccine

0.5ml to be administered twice weekly for 18 weeks (36 doses)

BIOLOGICAL

Placebo

0.5ml buffered saline placebo to be administered twice weekly for 18 weeks (36 doses)

BIOLOGICAL

HS110 vaccine

0.5 mls to be dosed twice weekly for 18 weeks (36 doses)

Trial Locations (1)

75201

Mary Crowley Cancer Research Centers, Dallas

Sponsors

Lead Sponsor

Heat Biologics
All Listed Sponsors
lead

Heat Biologics

INDUSTRY